Patents by Inventor Shawn P. Allwein

Shawn P. Allwein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10632119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 28, 2020
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused Bicyclic 2,4-Diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20190328735
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: October 26, 2018
    Publication date: October 31, 2019
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives
    Patent number: 10259794
    Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: April 16, 2019
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Roger P. Bakale, Dale R. Mowrey, Daniel E. Petrillo, Sander Kluwer
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 10111872
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: October 30, 2018
    Assignee: CEPHALON, INC.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • METHODS FOR PREPARING FUSED BICYCLIC 2, 4-DIAMINOPYRIMIDINE DERIVATIVES
    Publication number: 20170369451
    Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
    Type: Application
    Filed: December 23, 2015
    Publication date: December 28, 2017
    Inventors: Shawn P. ALLWEIN, Roger P. BAKALE, Dale R. MOWREY, Daniel E. PETRILLO, Sander KLUWER
  • FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR
    Publication number: 20170173017
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: March 7, 2017
    Publication date: June 22, 2017
    Inventors: Shawn P. Allwein, Laurent Courvoisier (deceased), Martin J. Jacobs, Gregory R. Ott
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9623026
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: April 18, 2017
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR
    Publication number: 20160243119
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: May 4, 2016
    Publication date: August 25, 2016
    Inventors: Shawn P. Allwein, Laurent Courvoisier (deceased), Martin J. Jacobs, Gregory R. Ott
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9339502
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: May 17, 2016
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20150374693
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: August 12, 2015
    Publication date: December 31, 2015
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Tricyclic Derivatives and Their Pharmaceutical Use and Compositions
    Publication number: 20150368257
    Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomeric forms, all mixtures of stereoisomeric forms, and salts of these compounds. This application also relates to compositions comprising compounds of Formula I, stereoisomeric forms, all mixtures of stereoisomeric forms, and salts thereof and uses therefor.
    Type: Application
    Filed: August 21, 2015
    Publication date: December 24, 2015
    Inventors: Shawn P. Allwein, George C. Morton, Gerard C. Rosse, Yi Wang
  • Fused bicyclic 2,4-diaminopyrimidine derivative as a dual ALK and FAK inhibitor
    Patent number: 9132128
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: September 15, 2015
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Tricyclic derivatives and their pharmaceutical use and compositions
    Patent number: 9115147
    Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomeric forms, all mixtures of stereoisomeric forms, and salts of these compounds. This application also relates to compositions comprising compounds of Formula I, stereoisomeric forms, all mixtures of stereoisomeric forms, and salts thereof and uses therefor.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: August 25, 2015
    Assignee: Cephalon, Inc.
    Inventors: Shawn P. Allwein, George C. Morton, Gerard C. Rosse, Yi Wang
  • Fused Bicyclic 2,4-diaminopyrimidine Derivative as a Dual ALK and FAK Inhibitor
    Publication number: 20150011561
    Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
    Type: Application
    Filed: September 2, 2014
    Publication date: January 8, 2015
    Inventors: Shawn P. Allwein, Laurent Courvoisier, Martin J. Jacobs, Gregory R. Ott
  • Method for purifying a fused pyrrolocarbazole derivative
    Patent number: 8884014
    Abstract: The present invention relates a method for purifying a fused pyrrolocarbazole compound known as 11-isobutyl-2-methyl-8-(2-pyrimidinylamino)-2,5,6,11,12,13-hexahydro-4Hindazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one using an acid complex thereof. The present invention also relates to a crystalline form of the acid complex.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: November 11, 2014
    Assignees: Cephalon, Inc., Teva Sante
    Inventors: Shawn P. Allwein, Arnaud Grandeury, Guy Piacenza, Sebastien Rose
  • Tricyclic Derivatives and Their Pharmaceutical Use and Compositions
    Publication number: 20120277186
    Abstract: This application relates to tricyclic compounds of Formula I: including all stereoisomeric forms, all mixtures of stereoisomeric forms, and salts of these compounds. This application also relates to compositions comprising compounds of Formula I, stereoisomeric forms, all mixtures of stereoisomeric forms, and salts thereof and uses therefor.
    Type: Application
    Filed: June 21, 2012
    Publication date: November 1, 2012
    Applicant: Cephalon, Inc.
    Inventors: Shawn P. Allwein, George C. Morton, Gerard C. Rosse, Yi Wang